OBJECTIVE: To evaluate the relationship between CSF hypocretin-1 levels and clinical profiles in narcolepsy and CNS hypersomnia in Norwegian patients. METHOD: CSF hypocretin-1 was measured by a sensitive radioimmunoassay in 47 patients with narcolepsy with cataplexy, 7 with narcolepsy without cataplexy, 10 with idiopathic CNS hypersomnia, and a control group. RESULTS: Low hypocretin-1 values were found in 72% of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy. Patients with low CSF hypocretin-1 levels reported more extensive muscular involvement during cataplectic attacks than patients with normal levels. Hypnagogic hallucinations and sleep paralysis occurred more frequently in patients with cataplexy than in the other patient groups, but with no correlation to hypocretin-1 levels. CONCLUSION: About three quarters of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy had low CSF hypocretin-1 values, and appear to form a distinct clinical entity. Narcolepsy without cataplexy could not be distinguished from idiopathic CNS hypersomnia by clinical symptoms or biochemical findings.
OBJECTIVE: To evaluate the relationship between CSF hypocretin-1 levels and clinical profiles in narcolepsy and CNS hypersomnia in Norwegian patients. METHOD: CSF hypocretin-1 was measured by a sensitive radioimmunoassay in 47 patients with narcolepsy with cataplexy, 7 with narcolepsy without cataplexy, 10 with idiopathic CNS hypersomnia, and a control group. RESULTS: Low hypocretin-1 values were found in 72% of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy. Patients with low CSF hypocretin-1 levels reported more extensive muscular involvement during cataplectic attacks than patients with normal levels. Hypnagogic hallucinations and sleep paralysis occurred more frequently in patients with cataplexy than in the other patient groups, but with no correlation to hypocretin-1 levels. CONCLUSION: About three quarters of the HLA DQB1*0602 positive patients with narcolepsy and cataplexy had low CSF hypocretin-1 values, and appear to form a distinct clinical entity. Narcolepsy without cataplexy could not be distinguished from idiopathic CNS hypersomnia by clinical symptoms or biochemical findings.
Authors: K M Gautvik; L de Lecea; V T Gautvik; P E Danielson; P Tranque; A Dopazo; F E Bloom; J G Sutcliffe Journal: Proc Natl Acad Sci U S A Date: 1996-08-06 Impact factor: 11.205
Authors: R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa Journal: Cell Date: 1999-08-20 Impact factor: 41.582
Authors: Christian R Baumann; Emmanuel Mignot; Gert Jan Lammers; Sebastiaan Overeem; Isabelle Arnulf; David Rye; Yves Dauvilliers; Makoto Honda; Judith A Owens; Giuseppe Plazzi; Thomas E Scammell Journal: Sleep Date: 2014-06-01 Impact factor: 5.849
Authors: Glenda Keating; Donald L Bliwise; Prabhjyot Saini; David B Rye; Lynn Marie Trotti Journal: Scand J Clin Lab Invest Date: 2017-05-24 Impact factor: 1.713
Authors: Lynn Marie Trotti; Prabhjyot Saini; Donald L Bliwise; Amanda A Freeman; Andrew Jenkins; David B Rye Journal: Ann Neurol Date: 2015-06-30 Impact factor: 10.422